Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MLTX 
MoonLake Immunotherapeutics (MLTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: MLTX (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
16 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $13.08
1 Year Target Price $13.08
| 12 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 74.66% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 641.36M USD | Price to earnings Ratio - | 1Y Target Price 13.08 |
Price to earnings Ratio - | 1Y Target Price 13.08 | ||
Volume (30-day avg) 16 | Beta 1.1 | 52 Weeks Range 5.95 - 62.75 | Updated Date 11/2/2025 |
52 Weeks Range 5.95 - 62.75 | Updated Date 11/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.79 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.99% | Return on Equity (TTM) -40.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 124404458 | Price to Sales(TTM) - |
Enterprise Value 124404458 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -41.53 | Shares Outstanding 63501402 | Shares Floating 32543834 |
Shares Outstanding 63501402 | Shares Floating 32543834 | ||
Percent Insiders 11.03 | Percent Institutions 84.3 |
Upturn AI SWOT
MoonLake Immunotherapeutics
Company Overview
History and Background
MoonLake Immunotherapeutics was founded in 2021 and focuses on developing innovative therapies for immune-mediated diseases, particularly dermatological and rheumatological conditions. It emerged from a collaboration between a biotech incubator and researchers. Significant milestones include securing funding, initiating clinical trials for their lead product, and a successful IPO.
Core Business Areas
- Clinical Development: Focuses on conducting clinical trials to evaluate the safety and efficacy of Sonelokimab, MoonLake's lead product, in various indications.
- Research and Development: Dedicated to discovering and developing novel therapies targeting the underlying causes of immune-mediated diseases.
- Regulatory Affairs: Handles interactions with regulatory agencies like the FDA and EMA to obtain approvals for MoonLake's products.
Leadership and Structure
The leadership team consists of experienced executives in the biotechnology industry, including a CEO, CFO, and Chief Medical Officer. The organizational structure includes departments focused on R&D, clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Sonelokimab: Sonelokimab is MoonLake's lead product candidate, a Nanobody targeting IL-17A and IL-17F for the treatment of hidradenitis suppurativa (HS) and potentially other inflammatory conditions. Market share is currently 0% as it is still in clinical development. Competitors in the HS market include AbbVie (Humira, Skyrizi), Novartis (Cosentyx), and UCB (Bimzelx).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, driven by innovation, regulatory approvals, and market access. The immunology segment is growing due to increasing prevalence of autoimmune diseases and advancements in targeted therapies.
Positioning
MoonLake is positioning itself as a leader in developing targeted therapies for immune-mediated diseases, specifically focusing on addressing unmet needs in dermatology and rheumatology. Their nanobody technology offers potential advantages in terms of efficacy and safety.
Total Addressable Market (TAM)
The TAM for hidradenitis suppurativa and other IL-17 related diseases is estimated at several billions of dollars annually. MoonLake's Sonelokimab aims to capture a significant portion of this market upon approval.
Upturn SWOT Analysis
Strengths
- Novel Nanobody technology platform
- Strong leadership team with experience in immunology
- Promising clinical trial results for Sonelokimab
- Focus on unmet needs in dermatology and rheumatology
- Strong financial backing
Weaknesses
- Dependence on the success of Sonelokimab
- Lack of commercialized products
- Limited manufacturing capacity
- High cash burn rate
- Susceptible to Clinical Trial failure
Opportunities
- Expansion of Sonelokimab into new indications
- Potential for partnerships with larger pharmaceutical companies
- Advancements in nanobody technology
- Increasing prevalence of immune-mediated diseases
- Acquisition by a larger pharmaceutical entity
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing therapies
- Patent expirations
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- ABBV
- NVS
- UCB
Competitive Landscape
MoonLake's nanobody technology offers a potential competitive advantage over existing therapies. However, they face competition from established pharmaceutical companies with greater resources and marketing capabilities. The competitive landscape is rapidly evolving with the development of new targeted therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as MoonLake is a relatively young company. Growth potential is tied to the clinical development and commercialization of Sonelokimab.
Future Projections: Future growth projections are based on analyst estimates for Sonelokimab's peak sales potential, which could reach several billion dollars if approved. Revenue projections rely heavily on successful clinical trials and regulatory approvals.
Recent Initiatives: Recent strategic initiatives include initiating Phase 3 trials for Sonelokimab in hidradenitis suppurativa and exploring its potential in other indications.
Summary
MoonLake Immunotherapeutics is a clinical-stage biotech company with a promising lead product candidate, Sonelokimab, and innovative nanobody technology. The company's success depends on the successful completion of clinical trials and regulatory approvals. They face competition from established players in the immunology market but their technology offers unique potential. Investors should watch closely for Phase 3 trial results and partnership opportunities.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MoonLake Immunotherapeutics
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-10-20 | Co-Founder, CEO & Director Dr. Jorge Santos da Silva Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 100 | Website https://www.moonlaketx.com |
Full time employees 100 | Website https://www.moonlaketx.com | ||
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.